Skip to main content
Equibles
INBP logo

INBP · Integrated Biopharma Inc

Track INBP — free

Use INBP with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research INBP.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.18 At close · Oct 15
Rebalance outlook locked
Market Cap
$5.59M
Shares
31.06M
Volume · Oct 15 600 Avg daily vol (3M) 13.72K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.18 Open$0.18 Day$0.18–0.18 52W close$0.15–0.38 Avg vol 30d16K Short int4 · 0.0% float · 1.0d Short vol50% DataJan 2020–Oct 2026 Filing10-K · Sep 25

Up next

Latest filing: 10-K
filed Sep 25, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$43.87M
Trailing 12 months
Net income (TTM)
−$2.84M
Trailing 12 months
Revenue growth YoY
-30.9%
Year over year
Operating margin
-6.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
16.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-1.4%
Year over year · fewer shares
Price change (1Y)
-41.9%
Trailing year
Short interest
0.0%
Latest settlement · 1.0 days to cover
View all 122 metrics

Quarterly results

Revenue Net income Net loss
▲5.4% $13.62M $259,000 '25 Q1 ▲9.6% $12.61M $116,000 '25 Q2 ▲6.1% $13.95M $611,000 '25 Q3 ▲11.2% $14.18M −$178,000 '25 Q4* ▼6.8% $12.69M $123,000 '26 Q1 ▼10.6% $11.28M −$762,000 '26 Q2 ▼27.5% $10.11M −$837,000 '26 Q3 LATEST ▼30.9% $9.80M −$1.37M '26 Q4*

* Q4 derived as the full year minus Q1 to Q3.

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 17.3 · elevated Equity put/call 0.56
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −30%
below
Price vs 50-day avg +5%
above
RSI (14) 51
neutral
MACD trend Positive
52-week position 13%
near low
Volume (OBV) Bearish div.
distributing
Momentum
relative strength
Weak
1-month return +6%
trailing
6-month return −45%
trailing
YTD return −50%
this year
Relative strength −54%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
0.00% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Squeeze score 36
low risk · 0–100
Fundamentals
Weak
Revenue growth −7%
Y/Y
Gross margin 2%
contracting
EPS growth −400%
Y/Y
Free cash flow $895.0K
Balance sheet $1.3M
net cash
Quant / Vol
risk profile
Very High
Volatility 76%
annualized · 1-yr
Max drawdown −61%
past year
ATR 6.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
3 · 2 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−30% Bearish
Price vs 50-day avg
+5% Bullish
RSI (14)
51 Neutral
MACD trend
Positive Bullish
52-week position
13% Bearish
Volume (OBV)
Bearish div. Bearish
Market signals — smart money & positioning
No clear signal
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
0.00% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Price context
position in its 52-week range
Range low $0 Now $0 · 13% Range high $0
vs 200-day avg -30% vs 50-day avg +5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Packaged Foods — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
INBP
Integrated Biopharma Inc
this stock
$5.59M -50.0% -6.9% — 0.0%
JBS
Jbs N.V.
 $41.77B -13.5% — — 1.3%
KHC
Kraft Heinz Co
 $28.26B -3.1% -0.1% — 7.8%
GIS
General Mills Inc
 $17.87B -30.0% +4.1% — 7.7%
SJM
J M SMUCKER Co
 $13.85B +30.7% +3.7% — 4.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Short & Settlement
Short Interest
Shares short
4
Days to cover
1.0d
Change
0 sh
View
Short Volume
Short vol %
50%
As of
Oct 15, 2026
Short Total
View
Fails to Deliver
FTD shares
41.4K
Value
$12.4K
As of
Jun 9, 2025
View
Off-Exchange
Off-exchange %
99.4%
Week of
Sep 14, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$43.7M
Net income (FY)
$-2.8M
EPS diluted
$-0.09
View
Filings
SEC Filings
Latest
10-K
Filed
Sep 25, 2026
This year
10
View

Performance

5D 20D 120D MTD YTD
INBP -5.3% +5.9% -45.5% +12.5% -50.0%
SPY -0.3% +1.2% +8.1% +1.2% +13.2%
vs SPY -5.0% +4.7% -53.6% +11.3% -63.2%
Key facts CIK 1016504 Visit website Investor relations